據報金輝集團(00137.HK)再獲「第二支箭」支持 中票發行獲投資人積極參與
據《上海證券報》報道,「第二支箭」(民營企業債券融資支持工具)昨日(20日)支持金輝集團(00137.HK)2023年度第二期中期票據成功發行
該期中期票據由民企支持工具全額擔保增信,發行金額8億元人民幣,期限三年,發行利率4.28%,募集資金主要用於補充流動資金、保交樓項目建設及償還境內外債券等。
據悉,此次中期票據發行得到各類市場投資機構的高度關注,銀行、券商、保險、信託及公募基金等各類機構踴躍申購,且首次有私募基金參與「第二支箭」項下的房地產債券投資,反映市場對房地產業健康發展的信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.